secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001493152-24-018576
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix Q1 rev $5.9M, net income $0.8M; PUR1900 study wind down, cash runway into Q1 2026
--------------------------------------------------------------------------------

- Revenue $5.9M (up $4.4M YoY) due to Cipla contract modification catch-up.
- Net income $0.8M vs net loss $4.4M in prior year.
- Cash $16.3M; expects cash runway into Q1 2026.
- PUR1900 Phase 2b stopped (no safety concern); Pulmatrix bears no further dev cost, gets 2% royalty on ex-US sales.
- PUR3100 Phase 2-ready; seeking partnership for Phase 2 study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224018576/0001493152-24-018576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224018576/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer